Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Regains Nasdaq Compliance

NEW YORK (GenomeWeb News) – CombiMatrix today said that it has received notice from Nasdaq that it has regained full compliance with the exchange's minimum bid continued listing requirement.

The Irvine, Calif.-based molecular diagnostics developer was notified by Nasdaq in late June that it was not in compliance with the rule, which stipulates that a firm's shares must trade at $1 or above. If the bid price falls below this level for 30 consecutive business days it gets a warning that it could be delisted if its shares don't regain compliance within 180 calendar days.

Earlier this month CombiMatrix undertook a one-for-10 reverse stock split, which enabled the company to regain compliance.

Its shares were up 1 percent at $6.24 in early Thursday trade.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.